{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-408435","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2026-09-30T13:20:10+00:00","discovered_at":"2026-09-30T13:21:00.205558+00:00","generated_at":"2026-10-12T14:00:16.028723+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Q32 Bio reports positive SIGNAL-AA Part B bempikibart results in alopecia areata","bullets":["Bempikibart achieved 35.3% mean SALT reduction at Week 36 in mITT; SALT-20 was 40.0% (10/25) mITT and 30.3% (10/33) ITT in severe/very severe alopecia areata.","SALT 30 and SALT 50 responses each reached 44.0% (11/25) in mITT and 33.3% (11/33) in ITT at Week 36.","In the 16-week off-drug period, 18 patients entered; SALT-20 was 44%, SALT 30 was 61%, SALT 50 was 50%; maintenance occurred in 100% of 12 Week 36 responders and deepening in 42%.","Prior oral JAKi responders had 48.3% mean SALT reduction vs 4.8% for non-responders; JAK-naive patients had 44.1%.","Safety: no serious or Grade 3+ treatment-related AEs; most common TEAE was injection site reaction at 36.3%, all mild; Q32 plans registration-directed AA program in H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-408435","json":"https://secwatch.observer/filing/0001193125-26-408435.json","markdown":"https://secwatch.observer/filing/0001193125-26-408435.md","text":"https://secwatch.observer/filing/0001193125-26-408435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526408435/0001193125-26-408435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526408435/d13352d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T14:00:16.028723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}